Padagis Seeks To Challenge Hikma’s Kloxxado
Naloxone 8mg Nasal Spray Is Among Firm’s Latest First-To-File Targets
Padagis has set out two first-to-file ANDA submissions in the US, challenging Hikma’s Kloxxado as well as Evofem’s Phexxi. The former Perrigo Rx business has also just launched two limited-competition generics.
